Corcept Therapeutics (NASDAQ: CORT) presented final overall survival data from its Phase 3 ROSELLA trial of Lifyorli in combination with nab-paclitaxel for platinum-resistant ovarian cancer at the Society of Gynecologic Oncology Annual Meeting. The data were simultaneously published in The Lancet.

The trial showed patients treated with Lifyorli plus nab-paclitaxel experienced a 35% reduction in risk of death compared to patients receiving nab-paclitaxel alone. Median overall survival was 16.0 months for the combination therapy versus 11.9 months for nab-paclitaxel alone, representing a 4.1-month improvement.

The combination also demonstrated a 30% reduction in risk of disease progression compared to nab-paclitaxel monotherapy. The treatment was well-tolerated with adverse events comparable to the control arm.

Lifyorli received FDA approval in March 2026 for treating adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatments, including at least one with bevacizumab. The drug has been added to NCCN Guidelines as a preferred regimen for this patient population.

The ROSELLA trial enrolled 381 patients across multiple countries including the United States, Europe, South Korea, Brazil, Argentina, Canada and Australia. Patients were randomized to receive either relacorilant plus nab-paclitaxel or nab-paclitaxel alone.

Lifyorli represents the first FDA-approved selective glucocorticoid receptor antagonist. Corcept has submitted a marketing authorization application to the European Medicines Agency for the drug's approval in Europe.